Approval Alert: FDA Approves Eli Lilly’s Omvoh® (mirikizumab) to Treat Moderate to Severe UC

Eli Lilly announced that the FDA has approved its Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active ulcerative colitis (UC) in adults.

On 1 April 2023, Eli Lilly launched its insulin glargine (Rezvoglar®) biosimilar to Sanofi’s Lantus®, in the US.  

Omvoh® is currently being assessed by the TGA, and was accepted for assessment in July 2022.  It was also approved in the EU by the European Commission on 26 May 2023